Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking

Gina Chun Kost, Senthil Selvaraj, Young Bok Lee, Deog Joong Kim, Chang Ho Ahn, Brij B. Singh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Clavulanic acid is a CNS-modulating compound with exceptional blood-brain barrier permeability and safety profile. Clavulanic acid has been proposed to have anti-depressant activity and is currently entering Phase IIb clinical trials for the treatment of Major Depressive Disorder (MDD). Studies have also shown that clavulanic acid suppresses anxiety and enhances sexual functions in rodent and primate models by a mechanism involving central nervous system (CNS) modulation, although its detailed mechanism of action has yet to be elucidated. To further examine its potential as a CNS modulating agent as well as its mechanism of action, we investigated the effects of clavulanic acid in neuronal cells. Our results indicate that clavulanic acid enhances dopamine release in PC12 and SH-SY5Y cells without affecting dopamine synthesis. Furthermore, using affinity chromatography we were able to identify two proteins, Munc18-1 and Rab4 that potentially bind to clavulanic acid and play a critical role in neurosecretion and the vesicle trafficking process. Consistent with this result, an increase in the translocation of Munc18-1 and Rab4 from the cytoplasm to the plasma membrane was observed in clavulanic acid treated cells. Overall, these data suggest that clavulanic acid enhances dopamine release in a mechanism involving Munc18-1 and Rab4 modulation and warrants further investigation of its therapeutic use in CNS disorders, such as depression.

Original languageEnglish
Pages (from-to)170-175
Number of pages6
JournalNeuroscience Letters
Volume504
Issue number2
DOIs
Publication statusPublished - 24 Oct 2011
Externally publishedYes

Fingerprint

Clavulanic Acid
Dopamine
Munc18 Proteins
Central Nervous System
Neurosecretion
Central Nervous System Agents
Central Nervous System Diseases
Major Depressive Disorder
Therapeutic Uses
Blood-Brain Barrier
Affinity Chromatography
Primates
Rodentia
Permeability
Cytoplasm
Anxiety
Cell Membrane
Clinical Trials
Depression
Safety

Keywords

  • Clavulanic acid
  • Depression
  • Dopamine
  • Neurotransmitter release
  • Rab4/Munc18-1

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking. / Kost, Gina Chun; Selvaraj, Senthil; Lee, Young Bok; Kim, Deog Joong; Ahn, Chang Ho; Singh, Brij B.

In: Neuroscience Letters, Vol. 504, No. 2, 24.10.2011, p. 170-175.

Research output: Contribution to journalArticle

Kost, Gina Chun ; Selvaraj, Senthil ; Lee, Young Bok ; Kim, Deog Joong ; Ahn, Chang Ho ; Singh, Brij B. / Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking. In: Neuroscience Letters. 2011 ; Vol. 504, No. 2. pp. 170-175.
@article{ff8274b87dcb4b5b8e58dd23509bfec4,
title = "Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking",
abstract = "Clavulanic acid is a CNS-modulating compound with exceptional blood-brain barrier permeability and safety profile. Clavulanic acid has been proposed to have anti-depressant activity and is currently entering Phase IIb clinical trials for the treatment of Major Depressive Disorder (MDD). Studies have also shown that clavulanic acid suppresses anxiety and enhances sexual functions in rodent and primate models by a mechanism involving central nervous system (CNS) modulation, although its detailed mechanism of action has yet to be elucidated. To further examine its potential as a CNS modulating agent as well as its mechanism of action, we investigated the effects of clavulanic acid in neuronal cells. Our results indicate that clavulanic acid enhances dopamine release in PC12 and SH-SY5Y cells without affecting dopamine synthesis. Furthermore, using affinity chromatography we were able to identify two proteins, Munc18-1 and Rab4 that potentially bind to clavulanic acid and play a critical role in neurosecretion and the vesicle trafficking process. Consistent with this result, an increase in the translocation of Munc18-1 and Rab4 from the cytoplasm to the plasma membrane was observed in clavulanic acid treated cells. Overall, these data suggest that clavulanic acid enhances dopamine release in a mechanism involving Munc18-1 and Rab4 modulation and warrants further investigation of its therapeutic use in CNS disorders, such as depression.",
keywords = "Clavulanic acid, Depression, Dopamine, Neurotransmitter release, Rab4/Munc18-1",
author = "Kost, {Gina Chun} and Senthil Selvaraj and Lee, {Young Bok} and Kim, {Deog Joong} and Ahn, {Chang Ho} and Singh, {Brij B.}",
year = "2011",
month = "10",
day = "24",
doi = "10.1016/j.neulet.2011.09.032",
language = "English",
volume = "504",
pages = "170--175",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking

AU - Kost, Gina Chun

AU - Selvaraj, Senthil

AU - Lee, Young Bok

AU - Kim, Deog Joong

AU - Ahn, Chang Ho

AU - Singh, Brij B.

PY - 2011/10/24

Y1 - 2011/10/24

N2 - Clavulanic acid is a CNS-modulating compound with exceptional blood-brain barrier permeability and safety profile. Clavulanic acid has been proposed to have anti-depressant activity and is currently entering Phase IIb clinical trials for the treatment of Major Depressive Disorder (MDD). Studies have also shown that clavulanic acid suppresses anxiety and enhances sexual functions in rodent and primate models by a mechanism involving central nervous system (CNS) modulation, although its detailed mechanism of action has yet to be elucidated. To further examine its potential as a CNS modulating agent as well as its mechanism of action, we investigated the effects of clavulanic acid in neuronal cells. Our results indicate that clavulanic acid enhances dopamine release in PC12 and SH-SY5Y cells without affecting dopamine synthesis. Furthermore, using affinity chromatography we were able to identify two proteins, Munc18-1 and Rab4 that potentially bind to clavulanic acid and play a critical role in neurosecretion and the vesicle trafficking process. Consistent with this result, an increase in the translocation of Munc18-1 and Rab4 from the cytoplasm to the plasma membrane was observed in clavulanic acid treated cells. Overall, these data suggest that clavulanic acid enhances dopamine release in a mechanism involving Munc18-1 and Rab4 modulation and warrants further investigation of its therapeutic use in CNS disorders, such as depression.

AB - Clavulanic acid is a CNS-modulating compound with exceptional blood-brain barrier permeability and safety profile. Clavulanic acid has been proposed to have anti-depressant activity and is currently entering Phase IIb clinical trials for the treatment of Major Depressive Disorder (MDD). Studies have also shown that clavulanic acid suppresses anxiety and enhances sexual functions in rodent and primate models by a mechanism involving central nervous system (CNS) modulation, although its detailed mechanism of action has yet to be elucidated. To further examine its potential as a CNS modulating agent as well as its mechanism of action, we investigated the effects of clavulanic acid in neuronal cells. Our results indicate that clavulanic acid enhances dopamine release in PC12 and SH-SY5Y cells without affecting dopamine synthesis. Furthermore, using affinity chromatography we were able to identify two proteins, Munc18-1 and Rab4 that potentially bind to clavulanic acid and play a critical role in neurosecretion and the vesicle trafficking process. Consistent with this result, an increase in the translocation of Munc18-1 and Rab4 from the cytoplasm to the plasma membrane was observed in clavulanic acid treated cells. Overall, these data suggest that clavulanic acid enhances dopamine release in a mechanism involving Munc18-1 and Rab4 modulation and warrants further investigation of its therapeutic use in CNS disorders, such as depression.

KW - Clavulanic acid

KW - Depression

KW - Dopamine

KW - Neurotransmitter release

KW - Rab4/Munc18-1

UR - http://www.scopus.com/inward/record.url?scp=80053939592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053939592&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2011.09.032

DO - 10.1016/j.neulet.2011.09.032

M3 - Article

VL - 504

SP - 170

EP - 175

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -